Michael Wood

B Capital Group Management LP is a private equity and venture capital firm founded in 2014 by Howard Lee Morgan, Raj Ganguly, Eduardo Saverin. The firm is headquartered in Manhattan Beach, California.

Sichuan Clover Biopharmaceuticals, Inc is a clinical-stage biotechnology company based in Chengdu, China. Clover Biopharmaceuticals' mission is to leverage their trimer-tag technology and in-house manufacturing capabilities to develop and deliver innovative and affordable medical solutions. The Chinese company is committed to partnering with leading healthcare organizations to advance their breakthrough pipeline programs and deliver them to patients. The company's pipeline includes many vaccine and therapeutic candidates for the treatment of infectious disease, cancer, and autoimmune disease, created using trimer-tag platform technology. The company was founded in 2007 by Peng Liang, and Joshua Liang has been the CEO of the company since 2016.

Thermalin, Inc. engages in the development of insulin products for patients with diabetes. It offers stabilized, ultra-rapid, and highly concentrated; no refrigeration basal and mix; glucose-responsive smart basal; and StampPump insulins. The company was founded by Michael A. Weiss, Bruce H. Frank, and Richard Berenson in 2010 and is headquartered in Cleveland, OH.

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

Intrinsic Therapeutics, Inc. develops device-based therapies for soft-tissue injuries of the spine. It offers surgeons and patients better options for treating painful disc herniations that cause sciatica and low back pain. The company was founded by Gregory H. Lambrecht in 1999 and is headquartered in Woburn, MA.

STRM.Bio, Inc. is a pre-clinical biotechnology company based in Cambridge, MA. The company's goal is to make gene therapy safe for repeat dosing and to provide a future of medicine for patients with rare diseases worldwide. The company, which was founded by Jonathan Thon and has had him as CEO since incorporation, is backed by venture capital and focuses on developing and delivering targeted gene therapies using extracellular vesicles.

Delos Capital LLC (Delos Capital) is a private equity firm founded in 2013 by Mattew Constantino. The firm is headquartered in New York.

Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018.

Delos Advisors Ltd (Delos Capital) is a private equity and venture capital firm founded by Lin Zheng Chen in 2014. The firm is headquartered in Hong Kong.

Partillion Bioscience Corp. is an American company that specializes in providing a functional single-cell biology reagent platform. The company's nanovial technology allows for single-cell secretion analysis and other research capabilities. The company was founded by Joseph Michael de Rutte and Dino Di Carlo, with Joseph Michael de Rutte serving as CEO since incorporation.

Red Tree Venture Capital is a venture capital firm founded by Heath Lukatch. The firm is headquartered in portola, California.

Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA.

Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation.

Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation.

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

Xeraya Capital Sdn. Bhd. (Xeraya Capital) is a venture capital firm founded in 2006 by Amirul Fares Wan Zahir. The firm is headquartered in Kuala Lumpur, Malaysia.

Aria CV, Inc. develops medical devices. It designed to improve the lives of patients living with the disease of pulmonary hypertension. The company was founded by John Scandurra and Karl Vollmers in 20101 and is headquartered in St. Paul, MN.